



## 2023 MX-A Intended Responses

### ANTIBODY SPECIFICITIES by FLOW

MX-01P		MX-02P	
Class I Results	Class II Results	Class I Results	Class II Results
B45, B41, B50, B60, B49, B44, B72, B13, B62, B71, B76, B61, B48, B35, B18, B53, B51, B38, B78, B47, B39, B77, B75, B52, B59, B64, B37, B8, B65, C9, C10, A25, B82, B46	Negative	Negative	Negative
MX-03P		MX-04P	
Class I Results	Class II Results	Class I Results	Class II Results
A2, B57, A69, A68, B58, A32, A23, B49, B63, B51, B38, A25, A24, B53, B77, B59, B*27:05, B37, B52, B13, B44, B47	DR7, DQ9, DQ7, DQ8, DR52, DR12, DR9, DQ6, DQ4, DQ2	B7, B42, B67, B81, B56, B55, B82, B27, B54, A*02:03, B73	Negative

CDC- complement-dependent cytotoxicity antibody specificities are no longer a reportable method due to inadequate group size.

### CROSSMATCH RESULTS

MX-01P (1 <sup>st</sup> Set)		
Method	Against MX-05C	Against MX-06C
Direct Cytotoxicity	T and B - both NEGATIVE	T and B - both NEGATIVE
Flow	T and B - both <b>POSITIVE</b>	T and B - both NEGATIVE
MX-02P (2 <sup>nd</sup> Set)		
Method	Against MX-05C	Against MX-06C
Direct Cytotoxicity	T and B - both NEGATIVE	T and B - both NEGATIVE
Flow	T and B - both NEGATIVE	T and B - both NEGATIVE
MX-03P (3 <sup>rd</sup> Set)		
Method	Against MX-05C	Against MX-06C
Direct Cytotoxicity	T and B - both <b>POSITIVE</b>	T and B - both <b>POSITIVE</b>
Flow	T and B - both <b>POSITIVE</b>	T and B - both <b>POSITIVE</b>
MX-04P (4 <sup>th</sup> Set)		
Method	Against MX-05C	Against MX-06C
Direct Cytotoxicity	T and B - both NEGATIVE	T and B - both NEGATIVE
Flow	T and B - both NEGATIVE	T and B - both <b>POSITIVE</b>